Type 2 diabetes with albuminuric CKD — ABIM Board MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Start an SGLT2 inhibitor with proven kidney and cardiovascular benefit
The best answer is “Start an SGLT2 inhibitor with proven kidney and cardiovascular benefit”. Albuminuric diabetic CKD at this eGFR is a strong indication for an SGLT2 inhibitor, layered on renin-angiotensin inhibition. Its cardiorenal benefit is not dependent on needing a large A1C reduction. Glyburide creates prolonged hypoglycemia risk, short-acting nifedipine is not equivalent kidney protection, and delaying treatment sacrifices benefit.
Reference: KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease: https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf